Our original, patented technology D-TAC (Dextran-based TAM-activating conjugates) demonstrates strong anti-tumor activity by phenotypically changing immunosuppressive tumor macrophages into immune-boosting ones. We are currently seeking partners to develop our technology for clinical applications.